Skip to content
10-K

Annual Report

Matinas BioPharma Holdings, Inc. MTNB

0001493152-26-014132

← back to feed
Filed
Mar 31, 2026 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding FY 2025 · Mar 26, 2026 6.41M sh
Shares Diluted FY 2025 · Dec 31, 2025 5.47M sh
Shares Diluted FY 2025 · Dec 31, 2024 4.87M sh
Operating Cash Flow FY 2025 · Dec 31, 2025 −$7.01M
Operating Cash Flow FY 2025 · Dec 31, 2024 −$15.89M
Cash And Equivalents FY 2025 · Dec 31, 2025 $4M
Cash And Equivalents FY 2025 · Dec 31, 2024 $7.28M
Cash And Equivalents FY 2025 · Dec 31, 2023 $4.79M
Stockholders Equity FY 2025 · Dec 31, 2025 $4.83M
Stockholders Equity FY 2025 · Dec 31, 2024 $7.59M
Stockholders Equity FY 2025 · Dec 31, 2023 $19.25M
Current Liabilities FY 2025 · Dec 31, 2025 $1.46M
Current Liabilities FY 2025 · Dec 31, 2024 $2.67M
Total Liabilities FY 2025 · Dec 31, 2025 $2.38M
Total Liabilities FY 2025 · Dec 31, 2024 $5.05M
Current Assets FY 2025 · Dec 31, 2025 $4.08M
Current Assets FY 2025 · Dec 31, 2024 $8.03M
Total Assets FY 2025 · Dec 31, 2025 $7.21M
Total Assets FY 2025 · Dec 31, 2024 $12.64M
Eps Diluted FY 2025 · Dec 31, 2025 −$2.00
Eps Diluted FY 2025 · Dec 31, 2024 −$4.98
Eps Basic FY 2025 · Dec 31, 2025 −$2.00
Eps Basic FY 2025 · Dec 31, 2024 −$4.98
Sga Expense FY 2025 · Dec 31, 2025 $6.88M
Sga Expense FY 2025 · Dec 31, 2024 $8.73M
Rd Expense FY 2025 · Dec 31, 2025 $85K
Rd Expense FY 2025 · Dec 31, 2024 $11.43M
Net Income FY 2025 · Dec 31, 2025 −$10.35M
Net Income FY 2025 · Dec 31, 2024 −$24.25M
Operating Income FY 2025 · Dec 31, 2025 −$6.96M
Operating Income FY 2025 · Dec 31, 2024 −$24.59M